News Conference News AHA 2025 Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials Yael L. Maxwell November 13, 2025
News Conference News AHA 2024 Infections No More Likely With Reconditioned Versus New Pacemakers Yael L. Maxwell November 22, 2024
News Conference News AHA 2023 Large Study Affirms Safety of Pulsed-Field Ablation, Reveals Some Rare Complications Todd Neale November 13, 2023
News Conference News AHA 2023 Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics Todd Neale November 11, 2023
News Conference News AHA 2022 Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering Caitlin E. Cox November 08, 2022
News Conference News AHA 2021 Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data Yael L. Maxwell November 15, 2021
News Conference News AHA 2020 Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT Shelley Wood November 15, 2020
News Conference News AHA 2019 Inclisiran Slashes LDL in ASCVD Patients: ORION-10 Yael L. Maxwell November 16, 2019
News Conference News AHA 2019 COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine Caitlin E. Cox November 16, 2019
News Conference News AHA 2017 GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS Yael L. Maxwell November 14, 2017
News Conference News AHA 2016 No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION Shelley Wood November 13, 2016